This project addresses one of the most disabling complications of dopaminergic therapy in Parkinson's disease, namely the development of involuntary movements named dyskinesias. The mechanisms underlying dyskinesias remain unknown, and we lack specific and effective treatments to eradicate them. Studies in animal models have shown that the striatal levels of the chronic transcription factor (FosB consistently increase during chronic levodopa treatment. Therefore, it has been hypothesized that (FosB may regulate the genes responsible for altered responses to dopaminergic drugs. Here, we will test the effects of the transgenic manipulation of (FosB protein expression in non-human primates. The novel approach taken in this project may address pathophysiologic aspects and help develop new therapies. The project includes three specific aims. In the first aim, we will assess the behavioral and molecular changes following the overexpression of (FosB in the striatum of parkinsonian monkeys using a viral vector- mediated gene delivery.
The second aim will examine the basal ganglia circuitry of these animals using electrophysiologic recordings and correlate them with the development of dyskinesias. And the third aim will confirm the role of (FosB by down-regulating the expression of the endogenous gene in rats and monkeys. This project employs diverse experimental approaches across disciplines to address an important health problem. From the construction of viral vectors, to the in vitro testing, to the final evaluations of motor behavior and physiologic correlates in primates, this sequence of translational studies is designed to establish the mechanistic role of (FosB in the development of dyskinesias. Furthermore, these studies will assess the clinical application of (FosB gene silencing as a therapeutic strategy in complicated Parkinson's disease.

Public Health Relevance

One of the most disabling complications of dopaminergic therapy in Parkinson's disease is the development of involuntary movements named dyskinesias. The mechanisms underlying dyskinesias remain unknown, and we lack specific and effective treatments to eradicate them. This project is focused on the changes in gene expression within the brain that are associated with chronic drug therapy and lead to the development of dyskinesias. The goals of the project are to elucidate the mechanisms of dyskinesias and to test a novel therapy using gene silencing technologies in non-human primates.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01NS073994-04
Application #
8704741
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Sieber, Beth-Anne
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Emory University
Department
Neurology
Type
Schools of Medicine
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Phukan, Geetika; Shin, Tae Hwan; Shim, Jeom Soon et al. (2016) Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro. Sci Rep 6:29095
Masilamoni, Gunasingh J; Uthayathas, Subramanian; Koenig, Gerhard et al. (2016) Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile. Neuropharmacology 110:449-57
Park, Hye-Jin; Lee, Kang-Woo; Park, Eun S et al. (2016) Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann Clin Transl Neurol 3:769-780
Singh, Arun; Mewes, Klaus; Gross, Robert E et al. (2016) Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease. Proc Natl Acad Sci U S A 113:9629-34
Singh, Arun; Liang, Li; Kaneoke, Yoshiki et al. (2015) Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates. J Neurophysiol 113:1533-44
Chaudhuri, Amrita Datta; Kabaria, Savan; Choi, Doo Chul et al. (2015) MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death. J Biol Chem 290:12425-34
Potts, Lisa F; Park, Eun S; Woo, Jong-Min et al. (2015) Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann Neurol 77:930-41
Kabaria, Savan; Choi, Doo Chul; Chaudhuri, Amrita Datta et al. (2015) Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson's disease. FEBS Lett 589:319-25
Lee, Kang-Woo; Woo, Jong-Min; Im, Joo-Young et al. (2015) Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice. Neurobiol Aging 36:519-26
Singh, Arun; Gutekunst, Claire A; Uthayathas, Subramaniam et al. (2015) Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates. Neurosci Bull 31:705-13

Showing the most recent 10 out of 25 publications